Clinical Trial

CAR-T Followed by Bispecific Antibodies

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-05-27
notable Enrollment reduced: 42 -> 23 participants 2026-05-27
Trial Details
NCT Number NCT04889716
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Genentech, Inc.
Conditions Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
Enrollment 23 participants
Start Date 2021-11-05
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-26